Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.

Wang, Kai; Schriver, Brian J; Aschar-Sobbi, Roozbeh; Yi, Alex Y; Feric, Nicole T; Graziano, Michael P

Wang, Kai; Schriver, Brian J; Aschar-Sobbi, Roozbeh; Yi, Alex Y; Feric, Nicole T; Graziano, Michael P.

Afiliação

Wang K; Valo Health, Inc., Department of Discovery Research, New York, NY, United States.
Schriver BJ; Valo Health, Inc., Department of Discovery Research, New York, NY, United States.
Aschar-Sobbi R; Valo Health, Inc., Department of Discovery Research, New York, NY, United States.
Yi AY; Valo Health, Inc., Department of Discovery Research, New York, NY, United States.
Feric NT; Valo Health, Inc., Department of Discovery Research, New York, NY, United States.
Graziano MP; Valo Health, Inc., Department of Discovery Research, New York, NY, United States.

Front Bioeng Biotechnol ; 11: 1227184, 2023.

Article em En | MEDLINE | ID: mdl-37771571